This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation.
Drug repurposing’s potential to target undruggable molecules is showing huge promise for its ability to accelerate the development of new therapies and improve patient outcomes. They also provide a level playing field for academics, biotech companies, and pharma giants to compete on.
Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.
billion in 2023 attributable to its laboratory products and biopharma services segment (53.8% By type of service, clinical research services accounted for the lion’s share of the North American CRO services market, followed by early-phase development services, laboratory services, and consulting services. of total revenue).
Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies. TISSIUM – France’s TISSIUM announced Michel Thérin has been appointed to the company ’ s board of directors. Thérin is the president of Advanced Therapies at Siemens Healthineers. Immune Regulation – U.K.-based
With its technology, the company wants to change the way that biopharma companies plan clinical trials and develop oncology drugs. This is all about getting the right drugs to the right patients at the right time as soon as possible to personalize the treatment of their therapies, primarily in oncology,” said Vennare.
Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.
Data generation for drug discovery extends beyond the internet, encompassing data from laboratory instruments, empathic increase in radiomic output, and real-world evidence (RWE) from clinical settings ( Figure 1 ). Techbio companies have initiated this approach.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content